![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200097LOGO "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")
Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
Hard-hit Novo Nordisk still has M&A 'on the radar' post-Ablynx setback, CEO says | Fierce Pharma
novonordiskannualreport2
Microsoft Highlights HoloLens Partnership With Novo Nordisk
Novo Nordiskt to invest more than 17 billion DKK in manufacturing facilities - Nordic Life Science – the leading Nordic life science news service
AstraZeneca, Sanofi, Novo Nordisk Battle HHS on Drug Discounts
Novo Nordisk - Not As Promising As It Looks (NYSE:NVO) | Seeking Alpha
The Zacks Analyst Blog Highlights Novo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron
Novo Nordisk sees faster profit growth on diabetes drug Ozempic
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna | Fierce Biotech
Novo Nordisk: An Investor's Guide to a Leading Biotech Company
Novo Nordisk breaks ground on nearly $2 billion diabetes medicine production facility in Clayton, North Carolina
Novo Nordisk gains as Wegovy supplier Catalent resolves manufacturing issues (NYSE:NVO) | Seeking Alpha
Novo Nordisk Stock (NYSE:NVO), Quotes and News Summary - Benzinga
Novo Nordisk's acquisition journey is driven by price pressure and a hunger for innovation
Form 6-K NOVO NORDISK A S For: Dec 31
Novo Nordisk launching additional US insulin affordability offerings in January 2020
